On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

Using CRISPR technology, scientists uncovered genes that control C-A-G genetic stumbles in Huntington's disease ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... He pointed out that ever since the Federal Reserve began cutting short-term rates in September 2024 ...

Despite its potential, CRISPR/Cas technology has faced significant ... the European Commission released a draft proposal in July 2023 aimed to “cut red tape and increase efficiency and efficacy ...

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays cut their price target on shares of CRISPR Therapeutics from $59.00 to $55. ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...